Howard Burris

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Burris Howard A; Taylor Charles W; Jones Suzanne F; Koch Kevin M; Versola Melissa J; Arya Niki; Fleming Ronald A; Smith Deborah A; Pandite Lini; Spector Neil; Wilding George
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Burris H A
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Hainsworth John D; Spigel David R; Burris Howard A; Markus Tiffanie M; Shipley Dianna; Kuzur Michel; Lunin Scott; Greco F Anthony
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Howard Burris (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Burris Howard A; Taylor Charles W; Jones Suzanne F; Koch Kevin M; Versola Melissa J; Arya Niki; Fleming Ronald A; Smith Deborah A; Pandite Lini; Spector Neil; Wilding George
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(21):6702-8.
2009: Burris H A
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Oncogene 2009;28 Suppl 1():S4-13.
2009: Hainsworth John D; Spigel David R; Burris Howard A; Markus Tiffanie M; Shipley Dianna; Kuzur Michel; Lunin Scott; Greco F Anthony
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Cancer 2009;115(10):2138-46.
2008: Storniolo Anna Maria; Pegram Mark D; Overmoyer Beth; Silverman Paula; Peacock Nancy W; Jones Suzanne F; Loftiss Jill; Arya Nikita; Koch Kevin M; Paul Elaine; Pandite Lini; Fleming Ronald A; Lebowitz Peter F; Ho Peter T C; Burris Howard A
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3317-23.
2008: Yardley Denise A; Burris Howard A; Farley Cindy P; Barton John H; Peacock Nancy W; Spigel David R; Greco F Anthony; Hainsworth John D
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
Clinical breast cancer 2008;8(3):242-8.
2008: Burris Howard A
Preclinical investigations with epothilones in breast cancer models.
Seminars in oncology 2008;35(2 Suppl 2):S15-21; quiz S39.
2008: Von Hoff Daniel D; Kuhn John G; Burris Howard A; Miller Larry J
Does intraosseous equal intravenous? A pharmacokinetic study.
The American journal of emergency medicine 2008;26(1):31-8.
2007: Hainsworth John D; Spigel David R; Sosman Jeffrey A; Burris Howard A; Farley Cindy; Cucullu Heather; Yost Kathleen; Hart Lowell L; Sylvester Linda; Waterhouse David M; Greco F Anthony
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
Clinical genitourinary cancer 2007;5(7):427-32.
2007: Greco F Anthony; Spigel David R; Kuzur Michel E; Shipley Dianna; Gray James R; Thompson Dana S; Burris Howard A; Yardley Denise A; Pati Asim; Webb Charles D; Gandhi Jitendra G; Hainsworth John D
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Clinical lung cancer 2007;8(8):483-7.
2007: Spigel David R; Hainsworth John D; Simons Lisa; Meng Christina; Burris Howard A; Yardley Denise A; Grapski Richard; Schreeder Marshall; Mallidi Padmaja V; Greco F Anthony;
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(9):854-61.
2007: Khambata-Ford Shirin; Garrett Christopher R; Meropol Neal J; Basik Mark; Harbison Christopher T; Wu Shujian; Wong Tai W; Huang Xin; Takimoto Chris H; Godwin Andrew K; Tan Benjamin R; Krishnamurthi Smitha S; Burris Howard A; Poplin Elizabeth A; Hidalgo Manuel; Baselga Jose; Clark Edwin A; Mauro David J
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3230-7.
2007: Thomas Eva; Tabernero Josep; Fornier Monica; Conté Pierfranco; Fumoleau Pierre; Lluch Ana; Vahdat Linda T; Bunnell Craig A; Burris Howard A; Viens Patrice; Baselga José; Rivera Edgardo; Guarneri Valentina; Poulart Valerie; Klimovsky Judith; Lebwohl David; Martin Miguel
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3399-406.
2007: Aghajanian Carol; Burris Howard A; Jones Suzanne; Spriggs David R; Cohen Marvin B; Peck Ronald; Sabbatini Paul; Hensley Martee L; Greco F Anthony; Dupont Jakob; O'Connor Owen A
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1082-8.
2007: Fine Robert L; Shah Samir S; Moulton Thomas A; Yu Ing-Ru; Fogelman David R; Richardson Michael; Burris Howard A; Samuels Brian L; Assanasen Chatchawin; Gorroochurn Prakash; Hibshoosh Hanina; Orjuela Manuela; Garvin James; Goldman Frederick D; Dubovsky Daniel; Walterhouse David; Halligan Gregory
Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy.
Cancer chemotherapy and pharmacology 2007;59(4):429-37.
2006: Ajani J A; Safran H; Bokemeyer C; Shah M A; Lenz H-J; Van Cutsem E; Burris H A; Lebwohl D; Mullaney B
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
Investigational new drugs 2006;24(5):441-6.
2006: Burris Howard A
Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
Seminars in oncology 2006;33(2 Suppl 4):S3-16; quiz S41-2.
2005: Jones Suzanne F; Greco F Anthony; Gian Victor G; Miranda Fernando T; Raefsky Eric L; Hainsworth John D; Willcutt Noel T; Beschorner Aurelia F; Kennerly Glyndon; Burris Howard A
A Phase I trial of protracted oral fixed-dose temozolomide.
Cancer 2005;104(9):1985-91.
2005: Greco F Anthony; Thompson Dana S; Morrissey Lisa H; Erland Joan B; Burris Howard A; Spigel David R; Joseph Geetha; Corso Steven W; Spremulli Ellen; Hainsworth John D
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
The oncologist 2005;10(9):728-33.
2005: Spigel David R; Hainsworth John D; Burkett Emily R; Burris Howard A; Yardley Denise A; Thomas Melodie; Jones Suzanne F; Dickson Natalie R; Scullin Daniel C; Bradof James E; Rubinsak James R; Brierre Joseph E; Greco F Anthony
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Clinical lung cancer 2005;7(2):127-32.
2005: Burris Howard A
Recent updates on the role of chemotherapy in pancreatic cancer.
Seminars in oncology 2005;32(4 Suppl 6):S1-3.
2005: Burris Howard A; Hurwitz Herbert I; Dees E Claire; Dowlati Afshin; Blackwell Kimberly L; O'Neil Bert; Marcom Paul K; Ellis Matthew J; Overmoyer Beth; Jones Suzanne F; Harris Jennifer L; Smith Deborah A; Koch Kevin M; Stead Andrew; Mangum Steve; Spector Neil L
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5305-13.
2005: Jones Suzanne F; Kuhn John G; Greco F Anthony; Raefsky Eric L; Hainsworth John D; Dickson Natalie R; Thompson Dana S; Willcutt Noel T; White Melissa B; Burris Howard A
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Clinical lung cancer 2005;6(6):361-6.
2005: Spector Neil L; Xia Wenle; Burris Howard; Hurwitz Herbert; Dees E Claire; Dowlati Afshin; O'Neil Bert; Overmoyer Beth; Marcom Paul K; Blackwell Kimberly L; Smith Deborah A; Koch Kevin M; Stead Andrew; Mangum Steven; Ellis Matthew J; Liu Leihua; Man Albert K; Bremer Troy M; Harris Jennifer; Bacus Sarah
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2502-12.
2005: Burris Howard A; Rivkin Saul; Reynolds Robert; Harris Jules; Wax Arnold; Gerstein Hal; Mettinger Karl L; Staddon Arthur
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
The oncologist 2005;10(3):183-90.
2004: Greco F Anthony; Rodriguez Gladys I; Shaffer Don W; Hermann Robert; Litchy Sharlene; Yardley Denise A; Burris Howard A; Morrissey Lisa H; Erland Joan B; Hainsworth John D
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
The oncologist 2004;9(6):644-52.
2004: Burris Howard A
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
The oncologist 2004;9 Suppl 3():10-5.
2003: Jones Suzanne F; Gian Victor G; Greco F Anthony; Miranda Fernando T; Shipley Dianna L; Thompson Dana S; Hainsworth John D; Toomey Mitchell A; Willcutt Noel T; Burris Howard A
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):41-5.
2003: Jones Suzanne F; Burris Howard A; Hainsworth John D; Yardley Denise A; Raefsky Eric A; Miranda Fernando T; Kuzur Michel E; Willcutt Noel T; White Melissa B; Greco F Anthony
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):36-40.
2003: Hainsworth John D; Burris Howard A; Erland Joan B; Baker Margaret; Scullin Daniel C; Shaffer Don W; Greco F Anthony;
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Cancer investigation 2003;21(2):193-9.
2002: Hainsworth John D; Litchy Sharlene; Burris Howard A; Scullin Daniel C; Corso Steven W; Yardley Denise A; Morrissey Lisa; Greco F Anthony
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(20):4261-7.
2002: Greco F Anthony; Gray James R; Thompson Dana S; Burris Howard A; Erland Joan B; Barton John H; Litchy Sharlene; Houston Gerry A; Butts James A; Webb Charles; Scott Charles; Hainsworth John D
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Cancer 2002;95(6):1279-85.
2002: Hainsworth John D; Meluch Anthony A; McClurkan Suzanne; Gray James R; Stroup Steven L; Burris Howard A; Yardley Denise A; Bradof James E; Yost Kathleen; Ellis James K; Greco F Anthony
Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Cancer journal (Sudbury, Mass.) 2002;8(4):311-21.
2002: Hainsworth John D; Morrissey Lisa H; Scullin Daniel C; Houston Gerry Ann; Prasthofer Edgar F; Gray James R; Burris Howard A; Greco F Anthony
Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Cancer 2002;94(9):2426-33.
2002: Greco F Anthony; Burris Howard A; Litchy Sharlene; Barton John H; Bradof James E; Richards Paul; Scullin Daniel C; Erland Joan B; Morrissey Lisa H; Hainsworth John D
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1651-6.
2002: Jones Suzanne; Hainsworth John; Burris Howard A; Thompson Dana; Raefsky Eric; Johnson Valerie; Calvert Sharon; Bulanhagui Cecile; Lebwohl David; Greco F Anthony
Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies.
Investigational new drugs 2002;20(1):55-61.
2002: Jones Suzanne F; Greco F Anthony; Hainsworth John D; Patton Jeffrey W; Barton John H; Willcutt Noel T; Baker Margaret N; McGuirt Paul V; Levin Jeremey; Burris Howard A
A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
The oncologist 2002;7(5):444-50.
2001: Hainsworth J D; Burris H A; Billings F T; Bradof J E; Baker M; Greco F A
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Cancer 2001;92(9):2391-8.
2001: Greco F A; Burris H A; Gray J R; Raefsky E L; Dobbs C; Smith S; Rinaldi D; Morrissey L H; Erland J B; Litchy S; Hainsworth J D
Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network.
Cancer 2001;92(8):2142-7.
2001: Hainsworth J D; Burris H A; Meluch A A; Baker M N; Morrissey L H; Greco F A
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Cancer 2001;92(3):642-9.
2001: Hainsworth J D; Burris H A; Yardley D A; Bradof J E; Grimaldi M; Kalman L A; Sullivan T; Baker M; Erland J B; Greco F A
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(15):3500-5.
2001: Schwartz G; Johnson T R; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker J A; Von Hoff D D; Rowinsky E K
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1901-11.
2001: Hainsworth J D; Burris H A; Greco F A
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Seminars in oncology 2001;28(3 Suppl 9):21-5.
2001: Meluch A A; Greco F A; Burris H A; O'Rourke T; Ortega G; Steis R G; Morrissey L H; Johnson V; Hainsworth J D
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):3018-24.
2001: Greco F A; Gray J; Burris H A; Erland J B; Morrissey L H; Hainsworth J D
Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Cancer journal (Sudbury, Mass.) 2001;7(3):203-12.
2001: Hainsworth J D; Burris H A; Greco F A
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
Seminars in oncology 2001;28(2 Suppl 4):43-7.
2001: Hainsworth J D; Burris H A; Calvert S W; Willcutt N T; Scullin D C; Bramham J; Greco F A
Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.
Cancer investigation 2001;19(4):335-9.
2000: Greco F A; Burris H A; Erland J B; Gray J R; Kalman L A; Schreeder M T; Hainsworth J D
Carcinoma of unknown primary site.
Cancer 2000;89(12):2655-60.
2000: Greco F A; Burris H A; Hainsworth J D
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 4):31-4.
2000: Hainsworth J D; Burris H A; Litchy S; Morrissey L H; Barton J H; Bradof J E; Greco F A
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.
Cancer 2000;89(2):328-33.
2000: Hainsworth J D; Burris H A; Morrissey L H; Thomas M; Erland J B; Butts J A; Joseph G; Kalman L; Greco F A
Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Cancer journal (Sudbury, Mass.) 2000;6(3):151-6.
2000: Hainsworth J D; Burris H A; Morrissey L H; Litchy S; Scullin D C; Bearden J D; Richards P; Greco F A
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.
Blood 2000;95(10):3052-6.
2000: Schilsky R L; Bukowski R; Burris H; Hochster H; O'Rourke M; Wall J G; Mani S; Bonny T; Levin J; Hohneker J
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):415-20.
2000: Hainsworth J D; Burris H A; Litchy S; Erland J B; Hon J K; Brierre J E; Greco F A
Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Cancer 2000;88(6):1353-8.
2000: Greco F A; Erland J B; Morrissey L H; Burris H A; Hermann R C; Steis R; Thompson D; Gray J; Hainsworth J D
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):211-5.
2000: Burris H A; Hainsworth J D; Erland J B; Morrissey L H; Kalman L A; Hon J K; Scullin D C; Smith S W; Greco F A
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Seminars in oncology 2000;27(1 Suppl 2):9-13.
1999: Fields-Jones S; Koletsky A; Wilding G; O'Rourke M; O'Rourke T; Eckardt J; Yates B; McGuirt C; Burris H A
Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1307-10.
1999: Burris H A
The evolving role of oral topotecan.
Seminars in hematology 1999;36(4 Suppl 8):26-32.
1999: Villalona-Calero M A; Weiss G R; Burris H A; Kraynak M; Rodrigues G; Drengler R L; Eckhardt S G; Reigner B; Moczygemba J; Burger H U; Griffin T; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1915-25.
1999: Hainsworth J D; Burris H A; Greco F A
Weekly administration of docetaxel (Taxotere): summary of clinical data.
Seminars in oncology 1999;26(3 Suppl 10):19-24.
1999: Hainsworth J D; Burris H A; Erland J B; Morrissey L H; Meluch A A; Kalman L A; Hon J K; Scullin D C; Smith S W; Greco F A
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Cancer 1999;85(6):1269-76.
1999: Hainsworth J D; Burris H A; Morrissey L H; Greco F A
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
Cancer 1999;85(5):1179-85.
1999: Petit T; Aylesworth C; Burris H; Ravdin P; Rodriguez G; Smith L; Peacock N; Smetzer L; Bellet R; Von Hoff D D; Rowinsky E K
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):223-9.
1999: Diab S G; Baker S D; Joshi A; Burris H A; Cobb P W; Villalona-Calero M A; Eckhardt S G; Weiss G R; Rodriguez G I; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff D D; Rowinsky E K
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):299-308.
1999: Pazdur R; Royce M E; Rodriguez G I; Rinaldi D A; Patt Y Z; Hoff P M; Burris H A
Phase II trial of docetaxel for cholangiocarcinoma.
American journal of clinical oncology 1999;22(1):78-81.
1999: Gerrits C J; Schellens J H; Burris H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Von Hoff D D; Verweij J
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1999: Rinaldi D A; Kuhn J G; Burris H A; Dorr F A; Rodriguez G; Eckhardt S G; Jones S; Woodworth J R; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff D D
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Cancer chemotherapy and pharmacology 1999;44(5):372-80.
1998: Burris H
Weekly schedules of docetaxel.
Seminars in oncology 1998;25(6 Suppl 13):21-3.
1998: Valero V; Jones S E; Von Hoff D D; Booser D J; Mennel R G; Ravdin P M; Holmes F A; Rahman Z; Schottstaedt M W; Erban J K; Esparza-Guerra L; Earhart R H; Hortobagyi G N; Burris H A
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3362-8.
1998: Rothenberg M L; Sharma A; Weiss G R; Villalona-Calero M A; Eckardt J R; Aylesworth C; Kraynak M A; Rinaldi D A; Rodriguez G I; Burris H A; Eckhardt S G; Stephens C D; Forral K; Nicol S J; Von Hoff D D
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):733-8.
1998: Gerrits C J; Burris H; Schellens J H; Planting A S; van den Burg M E; Rodriguez G I; van Beurden V; Loos W J; Hudson I; Fields S; Verweij J; von Hoff D D
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: Hammond L A; Eckardt J R; Ganapathi R; Burris H A; Rodriguez G A; Eckhardt S G; Rothenberg M L; Weiss G R; Kuhn J G; Hodges S; Von Hoff D D; Rowinsky E K
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: Hainsworth J D; Burris H A; Erland J B; Thomas M; Greco F A
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2164-8.
1998: Gerrits C J; Burris H; Schellens J H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Fields S; Von Hoff D D; Verweij J
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: Schilsky R L; Hohneker J; Ratain M J; Janisch L; Smetzer L; Lucas V S; Khor S P; Diasio R; Von Hoff D D; Burris H A
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1450-7.
1998: Eckhardt S G; Baker S D; Eckardt J R; Burke T G; Warner D L; Kuhn J G; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg M L; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris H A; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Villalona-Calero M A; Eckardt J; Burris H; Kraynak M; Fields-Jones S; Bazan C; Lancaster J; Hander T; Goldblum R; Hammond L; Bari A; Drengler R; Rothenberg M; Hadovsky G; Von Hoff D D
A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):71-7.
1998: Peacock N W; Burris H A; Dieras V; Smith L; Rodriguez G I; Eckardt J R; Jones S F; Hardy J; Hohneker J; Bigley J; Von Hoff D D
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Investigational new drugs 1998;16(1):37-43.
1998: Burris H A; Raymond E; Awada A; Kuhn J G; O'Rourke T J; Brentzel J; Lynch W; King S Y; Brown T D; Von Hoff D D
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Investigational new drugs 1998;16(1):19-27.
1997: Raymond E; Burris H A; Rowinsky E K; Eckardt J R; Rodriguez G; Smith L; Weiss G; Von Hoff D D
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):1003-8.
1997: Burris H A; Dieras V C; Tunca M; Earhart R H; Eckardt J R; Rodriguez G I; Shaffer D S; Fields S M; Campbell E; Schaaf L; Kasunic D; Von Hoff D D
Phase I study with the DNA sequence-specific agent adozelesin.
Anti-cancer drugs 1997;8(6):588-96.
1997: Rowinsky E; Smith L; Rodriguez G; White L; Drengler R; Von Hoff D; Peacock N; Aylesworth C; Burris H; Ravdin P; Bellet R
Docetaxel in combination with fluorouracil: study design and preliminary results.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):33-5.
1997: Burris H A; Moore M J; Andersen J; Green M R; Rothenberg M L; Modiano M R; Cripps M C; Portenoy R K; Storniolo A M; Tarassoff P; Nelson R; Dorr F A; Stephens C D; Von Hoff D D
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2403-13.
1997: Creemers G J; Gerrits C J; Eckardt J R; Schellens J H; Burris H A; Planting A S; Rodriguez G I; Loos W J; Hudson I; Broom C; Verweij J; Von Hoff D D
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: Burris H; Storniolo A M
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 1():S18-22.
1997: Weiss G R; Burris H A; Eckhardt S G; Rodriguez G I; Sharma S; Valley A
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1997;17():178-94.
1996: Eckhardt S G; Burris H A; Eckardt J R; Weiss G; Rodriguez G; Rothenberg M; Rinaldi D; Barrington R; Kuhn J G; Masuo K; Sudo K; Atsumi R; Oguma T; Higashi L; Fields S; Smetzer L; Von Hoff D D
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):491-6.
1996: Jones S F; Burris H A
Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer.
The Annals of pharmacotherapy 1996;30(5):501-6.
1996: Rothenberg M L; Moore M J; Cripps M C; Andersen J S; Portenoy R K; Burris H A; Green M R; Tarassoff P G; Brown T D; Casper E S; Storniolo A M; Von Hoff D D
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(4):347-53.
1996: Rothenberg M L; Eckardt J R; Kuhn J G; Burris H A; Nelson J; Hilsenbeck S G; Rodriguez G I; Thurman A M; Smith L S; Eckhardt S G; Weiss G R; Elfring G L; Rinaldi D A; Schaaf L J; Von Hoff D D
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1128-35.
1996: Jones S F; Burris H A
Topoisomerase I inhibitors: topotecan and irinotecan.
Cancer practice 1996;4(1):51-3.
1995: Burris H A; Fields S; Peacock N
Docetaxel (Taxotere) in combination: a step forward.
Seminars in oncology 1995;22(6 Suppl 13):35-40.
1995: Bedikian A Y; Weiss G R; Legha S S; Burris H A; Eckardt J R; Jenkins J; Eton O; Buzaid A C; Smetzer L; Von Hoff D D
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2895-9.
1995: Ravdin P M; Burris H A; Cook G; Eisenberg P; Kane M; Bierman W A; Mortimer J; Genevois E; Bellet R E
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2879-85.
1995: Rinaldi D A; Burris H A; Dorr F A; Woodworth J R; Kuhn J G; Eckardt J R; Rodriguez G; Corso S W; Fields S M; Langley C
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2842-50.
1995: Weiss G R; Kuhn J G; Rizzo J; Smith L S; Rodriguez G I; Eckardt J R; Burris H A; Fields S; VanDenBerg K; von Hoff D D
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
Cancer chemotherapy and pharmacology 1995;35(5):397-402.
1994: Eckardt J R; Campbell E; Burris H A; Weiss G R; Rodriguez G I; Fields S M; Thurman A M; Peacock N W; Cobb P; Rothenberg M L
A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon.
American journal of clinical oncology 1994;17(6):498-501.
1994: Cobb P W; Degen D R; Clark G M; Chen S F; Kuhn J G; Gross J L; Kirshenbaum M R; Sun J H; Burris H A; Von Hoff D D
Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Journal of the National Cancer Institute 1994;86(19):1462-5.
1994: Burris H A; Fields S
Summary of data from in vitro and phase I vinorelbine (Navelbine) studies.
Seminars in oncology 1994;21(5 Suppl 10):14-9; discussion 19-20.
1994: O'Rourke T J; Weiss G R; New P; Burris H A; Rodriguez G; Eckhardt J; Hardy J; Kuhn J G; Fields S; Clark G M
Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812).
Anti-cancer drugs 1994;5(5):520-6.
1994: Burris H A; Awada A; Kuhn J G; Eckardt J R; Cobb P W; Rinaldi D A; Fields S; Smith L; Von Hoff D D
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Anti-cancer drugs 1994;5(4):394-402.
1994: Shimada Y; Rothenberg M; Hilsenbeck S G; Burris H A; Degen D; Von Hoff D D
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Anti-cancer drugs 1994;5(2):202-6.
1994: Brown T D; O'Rourke T J; Kuhn J G; Craig J B; Havlin K; Burris H A; Cagnola J; Hamilton J M; Grindey G B; Satterlee W G
Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
Anti-cancer drugs 1994;5(2):151-9.
1994: Burris H A; Fields S M
Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Hematology/oncology clinics of North America 1994;8(2):333-55.
1994: Eckardt J R; Burris H A; Kuhn J G; Bissery M C; Klink-Alakl M; Clark G M; Von Hoff D D
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1994;86(1):30-3.
1994: O'Rourke T J; Brown T D; Havlin K; Kuhn J G; Craig J B; Burris H A; Satterlee W G; Tarassoff P G; Von Hoff D D
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
European journal of cancer (Oxford, England : 1990) 1994;30A(3):417-8.
1994: Von Hoff D D; Burris H A; Eckardt J; Rothenberg M; Fields S M; Chen S F; Kuhn J G
Preclinical and phase I trials of topoisomerase I inhibitors.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S41-5.
1994: Weiss G R; Burris H A; Eckardt J R; Fields S; O'Rourke T; Rodriguez G I; Rothenberg M L
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1994;15():130-51.
1993: Shaffer D W; Smith L S; Burris H A; Clark G M; Eckardt J R; Fields S M; Weiss G R; Rinaldi D A; Bowen K J; Kuhn J G
A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Cancer research 1993;53(24):5929-33.
1993: Rothenberg M L; Kuhn J G; Burris H A; Nelson J; Eckardt J R; Tristan-Morales M; Hilsenbeck S G; Weiss G R; Smith L S; Rodriguez G I
Phase I and pharmacokinetic trial of weekly CPT-11.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2194-204.
1993: Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):950-8.
1993: Rinaldi D A; Lippman S M; Burris H A; Chou C; Von Hoff D D; Hong W K
Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
Anti-cancer drugs 1993;4(1):33-6.
1993: Weiss G R; Burris H A; Eckardt J R; Fields S; Johnson R; O'Rourke T; Rodriguez G I; Rothenberg M L; Wall J
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1993;14():118-28.
1992: Von Hoff D D; McGill J; Davidson K; Forseth B; Atef Ebrahim el-Zayat A; Burris H
Preclinical leads for innovative uses for etoposide.
Seminars in oncology 1992;19(6 Suppl 13):10-3.
1992: Burris H A; Rothenberg M L; Kuhn J G; Von Hoff D D
Clinical trials with the topoisomerase I inhibitors.
Seminars in oncology 1992;19(6):663-9.
1992: Burris H A; Hanauske A R; Johnson R K; Marshall M H; Kuhn J G; Hilsenbeck S G; Von Hoff D D
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1992;84(23):1816-20.
1992: Wall J G; Burris H A; Von Hoff D D; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Anti-cancer drugs 1992;3(4):337-45.
1992: Brown T D; Burris H A; Eckardt J R; O'Rourke T J; Rodriguez G I; Wall J G; Weiss G R
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1992;13():115-55.
1991: Brown T D; Burris H A; Havlin K A; O'Rourke T J; Rodriguez G I; Wall J G; Weiss G R
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1991;12():111-46.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Howard Burris

Research Profile (preview)

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Howard Burris (preview)

All Publications